New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
10:00 EDTLNCO, Z, RDS.A, AAPL, SRPT, SMBL, BP, ATRS, RLGY, SNDK, DNKNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Apple (AAPL) initiated with a Buy at Citigroup... BP (BP) initiated with an Outperform at Exane BNP Paribas... Dunkin' Brands (DNKN) initiated with a Buy at UBS... Royal Dutch Shell (RDS.A) initiated with an Underperform at Exane BNP Paribas... SanDisk (SNDK) initiated with an Outperform at Credit Suisse... Silicon Laboratories (SLAB) initiated with an Outperform at Pacific Crest... Smart Balance (SMBL) initiated with a Top Pick at RBC Capital... Zillow (Z) initiated with an Equal Weight at Morgan Stanley... Sarepta (SRPT) initiated with an Outperform at Burrill... Realogy (RLGY) initiated with a Buy at CRT Capital... LinnCo (LNCO) initiated with a Strong Buy at Raymond James... Antares Pharma (ATRS) initiated with a Buy at Guggenheim.
News For A;SNDK;SMBL;Z;RLGY;SRPT;LNCO;ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 19, 2015
11:16 EDTSNDKSanDisk sees completing headcount reductions by end of this quarter
11:06 EDTSNDKSanDisk says in Q2 to date repurchased $100M in shares
Subscribe for More Information
10:57 EDTSNDKSanDisk targets 2016 for return to enterprise revenue growth
10:56 EDTSNDKSanDisk sees enterprise revenue contracting sequentially in Q2
Subscribe for More Information
10:49 EDTSNDKSanDisk rallies while presenting at conference
Shares of SanDisk (SNDK) are moving higher while the company is presenting at the J.P. Morgan Global Technology, Media and Telecom Conference. During its presentation, SanDisk management said that 15 nanometer technology is ramping to plan and that it expects "strong" sequential revenue growth in the second half of the year. Shares of SanDisk are up 1.7% to $68.66 in morning trading.
10:46 EDTSNDKSanDisk sees strong sequential revenue growth in 2H
Sees successful completion of embedded qualifications.
10:43 EDTSNDKSanDisk says 15 nanometer technology ramping to plan
Comments from J.P. Morgan Global Technology, Media and Telecom Conference.
May 18, 2015
19:12 EDTA, LNCOOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:02 EDTSNDKNAND pricing tracking ahead of expectations, says JPMorgan
JPMorgan said the NAND market is picking up and pricing is tracking ahead of expectations due to restocking momentum. The firm expects NAND market traction heading into 2H driven by new smartphone launches and a recovery in the PC market. Note SanDisk is leveraged to NAND.
10:01 EDTATRSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTLNCOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:51 EDTLNCOLinnCo downgraded to Sell from Neutral at Goldman
Subscribe for More Information
06:03 EDTATRSAntares Pharma initiated with an Overweight at Piper Jaffray
Target $3.50.
May 15, 2015
17:15 EDTRLGYPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use